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Background: Diagnostic imaging plays a relevant role in the care of patients with breast cancer (BC). Positron
Emission Tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) has been widely proven to be a clinical tool
suitable for BC detection and staging in which the glucose analog supplies metabolic information about the tumor.
A limited number of studies, sometimes controversial, describe possible associations between FDG uptake and
single nucleotide polymorphisms (SNPs). For this reason this field has to be explored and clarified. We investigated
the association of SNPs in GLUT1, HIF-1a, EPAS1, APEX1, VEGFA and MTHFR genes with the FDG uptake in BC.
Methods: In 26 caucasian individuals with primary BC, whole-body PET-CT scans were obtained and quantitative
analysis was performed by calculating the maximum Standardized Uptake Value normalized to body-weight
(SUVmax) and the mean SUV normalized to body-weight corrected for partial volume effect (SUVpvc). Human Gene
Mutation Database and dbSNP Short Genetic Variations database were used to analyze gene regions containing the
selected SNPs. Patient genotypes were obtained using Sanger DNA sequencing analysis performed by Capillary
Electrophoresis.
Results: BC patients were genotyped for the following nine SNPs: GLUT1: rs841853 and rs710218; HIF-1a:
rs11549465 and rs11549467; EPAS1: rs137853037 and rs137853036; APEX1: rs1130409; VEGFA: rs3025039 and MTHFR:
rs1801133. In this work correlations between the nine potentially useful polymorphisms selected and previously
suggested with tracer uptake (using both SUVmax and SUVpvc) were not found.
Conclusions: The possible functional influence of specific SNPs on FDG uptake needs further studies in human
cancer. In summary, this is the first pilot study, to our knowledge, which investigates the association between a
large panel of SNPs and FDG uptake specifically in BC patients. This work represents a multidisciplinary and
translational medicine approach to study BC where, the possible correlation between SNPs and tracer uptake, may
be considered to improve personalized cancer treatment and care.
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Breast cancer (BC) is the leading cause of cancer-related
death in women world-wide [1] and presents distinct
subtypes associated with different clinical outcomes.
Understanding this heterogeneity represents a key factor
for the development of targeted preventive and thera-
peutic interventions [2-4]. Upon cancer disease occur-
rence, survival outcomes seem to be dependent not only
on the histological type but also on the intensity of* Correspondence: valentina.bravata@polooncologicocefalu.it
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reproduction in any medium, provided the orlesion measured by 18F-fluoro-2-deoxy-D-glucose Posi-
tron Emission Tomography (FDG PET) uptake [5]. FDG
PET is a non-invasive diagnostic and prognostic tool
that assess tumour metabolism and it is used for treat-
ment planning and the evaluation of therapy response
[6]. To improve this technique, it is necessary to dis-
cover deregulated tumour-specific markers that may
serve as molecular targets for the imaging of cancer [7].
The completion of nine large genome-wide association
studies [8,9] introduced single-nucleotide polymor-
phisms (SNPs) as risk factors for BC disease [10]. Des-
pite considerable progress, their commercial exploitationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Bravatà et al. Journal of Experimental & Clinical Cancer Research 2013, 32:23 Page 2 of 9
http://www.jeccr.com/content/32/1/23in clinical applications remains controversial [11,12]. In
addition, the potential functional influence of specific
SNPs on tracer PET uptake needs further investigations
in human cancer diseases. Indeed, the first study de-
monstrating an association between a human SNP
(rs3025039 of the Vascular Endothelial Growth Factor A,
abbreviated as VEGFA) and FDG uptake in BC, has in-
cluded a restricted number of 37 ductal BC patients
without metastases [13].
Although, the possible correlation between gene poly-
morphisms and FDG uptake is considered an innovative
and interesting example of translational medicine ap-
proach, where information from multiple sources are
combined aiming to a more personalized care, the num-
ber of scientific papers is still limited [13-18]. Nowadays,
candidate targets used for these studies are polymor-
phisms in the GLUcose Transporter 1 gene (GLUT1 also
known as SLC2A1) and the following three hypoxia-
related genes: Hypoxia-Inducible Factor 1alpha (HIF-1a),
VEGFA and apurinic/apyrimidinic APEX nuclease 1
(APEX1) [13-18].
GLUT family members are often over-expressed in
most human malignancies [19] and are involved in
tumour initiation and progression. However, they are
already present in the respective non-cancerous tissue of
origin. The class I transporters (GLUT1), and to a much
less extent GLUT3, are the most frequently over-
expressed genes in cancer cells. Their over-expression
positively correlates with several adverse tumour charac-
teristics and PET uptake in BC [20] and various other
malignancies [21-23]. Regarding the role of GLUT1 on
PET imaging, only two authors have shown that
rs841853and rs710218 GLUT1 SNPs influence tracer
PET uptake [14,15]. These two SNPs were considered to
be able to determine variations on the behaviour of the
glucose transporter in various human diseases, such as
diabetic nephropathy and clear-cell renal carcinoma
[24,25], where a high significant allele frequency in the
population investigated was found, suggesting their po-
tential clinical application. The rs841853 SNP is located
in a non-protein coding region (intron 2 of the GLUT1
gene) and seems to have a role in recruiting glucose over
the membrane, accelerating growth cell rate. The
rs710218 SNP is positioned in the promoter region of
the GLUT1 gene adjacent to a putative HIF-1a binding
site [26]. HIF-1a controls oxygen delivery and metabolic
adaptation to hypoxia via angiogenesis and glycolysis, re-
spectively and it also regulates, under hypoxic condi-
tions, the expression of genes, like the GLUT1 gene.
Numerous clinico-pathological studies have demon-
strated that unlike mature normal tissues, 40%-80% of
human carcinomas, like melanomas, sarcomas, head and
neck, lung, breast and endometrial cancers contain ele-
vated cytoplasmic and nuclear HIF-1a levels [27-29]. Inaddition, Fu XS. et al. and Koukourakis MI. et al. showed
that HIF-1a gene polymorphisms, such as rs11549465
and rs11549467, affect its expression [30,31]. These
SNPs seem to be also related with FDG uptake as de-
scribed by Kim SJ. and co-workers [15].
Hypoxia-inducible factor 2 alpha (HIF-2a), also known
as endothelial PAS domain protein 1 (EPAS1), is another
member of the hypoxia-inducible factor family and
shares many similarities with HIF-1a [32,33]. However
several molecular, biochemical, and physiological studies
have established that HIF-1a and HIF-2a are not redun-
dant but have distinct functions [34]. To understand the
possible relationship of EPAS1 and the abovementioned
HIF-1a SNPs to FDG uptake, we analyzed the only two
EPAS1 missense mutations (rs137853037 and rs137853036)
with probable pathogenicity as described in the dbSNP
Short Genetic Variations database and in the Human Gene
Mutation Database where a collection of known gene
lesions responsible for human inherited diseases is found.
APEX1, a DNA base excision repair enzyme, has also
a role in transcriptional activation of HIF-1 and the hy-
poxia inducible factor-like factor (HLF). APEX1 poly-
morphisms have been the object of studies about in
several types of cancer including colorectal, breast and
non-small cell lung cancer (NSCLC) in order to evaluate
their role in cancer susceptibility, development and re-
sponse to radiotherapy [15,35]. Interestingly, in NSCLC
patients with the APEX1 rs1130409 TT genotype an as-
sociation, not fully clarified yet, between the abovemen-
tioned rs710218 GLUT1 SNP and FDG uptake was
shown [15].
Overall, all previous studies have investigated SNPs of
a limited number of genes. Furthermore, the type of can-
cer tissue varies, rendering difficult the evaluation of
their real impact on FDG PET uptake in specific cancer
types. To our knowledge, no studies have examined the
simultaneous presence and role of these specific poly-
morphisms in BC patients. Therefore, the purpose of
this preliminary research was to highlight possible asso-
ciations between the abovementioned SNPs of the
GLUT1, HIF-1a, EPAS1, APEX1 and VEGFA genes and
the FDG uptake, in order to identify a large panel of
SNPs, for imaging analysis that will allow a more per-
sonalized treatment program.
Methods
Patients
Thirty-three caucasian individuals with primary BC were
enrolled for a multidisciplinary project named “Tissue
characterization in primary BC: correlation with FDG-
PET uptake and with choline peak by proton nuclear
MR spectroscopy”. Inclusion criteria for genotyping ana-
lysis were: patients candidated for surgery of invasive BC
with a tumour size of at least 2 cm, as measured by
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treated with primary chemotherapy. Twenty-six BC pa-
tients were finally selected for genotyping analysis using
the abovementioned inclusion criteria. The study and
the consent procedure were performed according to the
Helsinki declaration and were approved by the Ethical
Committee (EC) of HSR G. Giglio hospital, Cefalù-Italy.
FDG PET-CT
Before surgical resection of primitive BC, all patients
underwent FDG PET-CT studies. The patients were
fasted for twelve hours before performing PET-CT scan,
and were injected intravenously with FDG (37MBq/
10 kg). Patients with a blood glucose level greater than
150 mg/dl were not included in the study. The weight of
each patient was measured the day of the PET-CT study.
Actual injected and residual radioactivity were measured
by the dose measurement system. PET-CT acquisition
started 50 min after radiotracer injection and images
were acquired from the top of the skull to the middle of
the thigh with the arms raised. Whole-body PET-CT
scans were obtained using a Discovery STE scanner
(General Electric Medical Systems), installed at the
Nuclear Medicine Department of LATO-HSR (Cefalù,
Italy). The system is a three-dimensional BGO 47 slice
PET scanner combined with an helical 8 slice CT scanner.
The PET-CT oncological protocol included a low dose CT
scan and a 3D PET whole body scan (2.5 min/bed position).
Patients breathed normally during the PET and CT exams.
PET images were reconstructed by a 3D ordered subset
expectation maximization algorithm (OSEM, 28 subsets, 2
iterations, 5.14 mm Gaussian post-smoothing) with correc-
tions for random, scatter and attenuation incorporated into
the iterative process.
Quantitative PET measurements
Quantitative analysis was performed calculating, for each
breast lesion, the maximum Standardized Uptake Value
(SUVmax) and the mean SUV (SUVpvc) normalized to
body-weight. Partial volume effect correction (PVC) was
performed to compensate spill in (signal from back-
ground region that goes inside the lesion) and spill out
(signal from the lesion that goes into background region)
effects in the SUVpvc [36,37]. Since the SUVmax is the
uptake index least affected by partial volume effect no
correction was applied.
Briefly, the PVC method is based on recovery coeffi-
cient (RC) curves obtained from NEMA 2001 IQ phan-
tom (equipped with six spheres of different sizes - from
10 mm to 37 mm- to account for size effect) as a func-
tion of PET measured metabolic volume and of PET
measured sphere-to-background ratio [38]. The meta-
bolic volume was calculated as the 60% isocontour of
the maximum pixel intensity automatically drawn on thePET lesion. The radioactivity concentration in the lesion
was measured as the average radioactivity concentration
within the metabolic volume. The background radio-
activity concentration was obtained as the average of
four circular ROIs positioned over the background
around the lesion. To apply the PVC correction method,
PET measured metabolic volumes and lesion-to-back-
ground ratios were considered within the following
ranges of RC curves: measured diameters (derived from
metabolic volume) from 0 to 4 cm and lesion-to-back-
ground ratios from 2 to 30.
BC patients genotyping
In this study BC patients were genotyped, by sequencing
analysis, for the following polymorphisms: GLUT1
rs841853 (also known as XbaI because is a restriction
fragment length polymorphism-RFLP) and rs710218
SNPs (also known as HpyCH4V); HIF-1a rs11549465
and rs11549467 SNPs; EPAS1 rs137853037 and
rs137853036 SNPs; APEX1 rs1130409 SNP; VEGFA
rs3025039 and MTHFR rs1801133 SNP.
Human Gene Mutation Database [39] and dbSNP
Short Genetic Variations database [40] were used to
analyze gene regions containing the selected SNPs.
Genomic DNA was extracted from peripheral blood
using QIAamp DNA blood mini kit, according to the
manufacturer’s specifications (Qiagen). After quality and
quantity analysis, genomic DNA was PCR amplified
using primers designed by the Primer3 software [41] and
listed in Table 1. PCR reactions were performed with 50
ng of genomic DNA in a total volume of 50 μL
containing 1X PCR Gold Buffer, 1,5 mM di MgCl2, 200
μM dNTPs, 200 nM of forward and reverse primer mix,
1.25 U of AmpliTaq Gold DNA Polymerase (Applied
Biosystems). The thermal cycle profile employed a 5-min
denaturing step at 94°C, followed by 35 cycles at 94°C
for 45 sec, 59°C for 45 sec, 72°C for 45 sec and a final
extension step of 5 min at 72°C.
Quality and quantity of PCR products were assessed on
the Bioanalyzer instrument (Agilent Technologies) and
were purified using QIAquick PCR purification kit
(Qiagen), according to the manufacturer’s specifications.
To perform DNA sequencing, purified amplicons were la-
belled with BigDye Terminator v3.1 Cycle Sequencing Kit
following the manufacturer’s standard protocol (Applied
Biosystems). The thermal cycle profile employed a 1 min
denaturing step at 96°C, followed by 25 cycles at 96°C for
10 sec, 54°C for 5 sec, 60°C for 3 min. Labelled samples
were purified with X-terminator purification kit according
to manufacturer’s standard protocol and loaded in 3500-
Dx Genetic Analyzer (Applied Biosystems) for separation
by capillary electrophoresis. Electropherograms and se-
quence files were analyzed using Sequencing Analysis and
SeqScape softwares (Applied Biosystems).
Table 1 Primers sequence used for genotyping analysis
Target gene polymorphism (rs number) Forward primer 5′ > 3′ Reverse primer 5′ > 3′ Template size (base pairs)
GLUT1 _Xba I G > T gtgcaacccatgagctaacaa aacccagcactctgtagcc 305
(rs841853)
GLUT1 _HpyCH4V −2841 A > T tgagaatggccttccctcaat tctgccttactcagcccatg 336
(rs710218)
HIF1a Pro582Ser cccaatggatgatgacttcc tctgtttggtgaggctgtcc 316
(rs11549465)
HIF1a Ala588Thr cccaatggatgatgacttcc tctgtttggtgaggctgtcc 316
(rs11549467)
EPAS1 Met535Val tgacacagccaagtctgagg ggctctcaacaagccacttc 902
(rs137853037)
EPAS1 Gly537Arg tgacacagccaagtctgagg ggctctcaacaagccacttc 902
(rs137853036)
APEX1 Asp148Glu gccagtgcccactcaaagtt cttgcgaaaggcttcatccc 176
(rs1130409)
VEGFA +936 C > T ctcctcacttggccctaacc gggtgggtgtgtctacagga 414
(rs3025039)
MTHFR Ala222Val tttctatggccaccaagtgcag gacactgttgctgggttttgg 716
(rs1801133)
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The association between the SUVmax and SUVpvc
values and genetic factors was analyzed using GraphPad
InStat software version 3.05, San Diego California USA.
Mann Whitney-U test and Fisher’s exact test were
performed. Differences in groups for the medians
SUVmax and SUVpvc values were tested. Differences
were considered significant when p value was less than
or equal to 0.05.Results
Patients
The average age of 26 selected BC patients for genotyp-
ing analysis was 56.9 y (age range, 36–88 y; SD, 15.6 y).FDG PET-CT & quantitative PET measurements
SUVmax and SUVpvc values are shown in Table 2. The
average of SUVmax was 7.67 ± 4.01 (range: 1.95-17.65;
95% confidence interval (C.I.) 6.05-9.29). The average of
SUVpvc was 7.58 ± 3.88 (range: 2.64-19.15;; 95% C.I.
6.02-9.15), the mean sphere-equivalent diameter of PET
measured metabolic volume was 1.39 ± 0.44 cm (range:
0.8-2.55; 95% C.I. 1.21-1.56) and the average PET mea-
sured lesion-to-background ratio was 12.12 ± 5.65
(range: 1.92-25.79; 95% C.I. 9.84-14.40). In all cases the
lesions had a measured sphere-equivalent diameter and
a measured lesion-to-background ratio within the range
of the RC curves. PET-TC images will be available in
confidence with the radiology reader upon request.BC patients mutation analysis of the eight SNPs panel
BC patients, were genotyped for the eight SNPs previously
introduced (GLUT1: rs841853 and rs710218; HIF-1a:
rs11549465 and rs11549467; EPAS1: rs137853037 and
rs137853036; APEX1: rs1130409; VEGFA: rs3025039).
Allele frequencies and the percentages of the three pos-
sible genotypes for each SNP were calculated. Deviations
of Hardy-Weinberg equilibrium were not observed for all
SNPs except for the rs3025039 VEGFA polymorphism
(Table 3).Association between SNPs and SUV values
In order to evaluate a potential association between the
SNPs and the PET tracer uptake, SUVmax and SUVpvc
values were used. Patients were divided in subgroups
according to SNP genotype and a Mann-Whittney statis-
tical test was performed to evaluate the differences in
SUVmax and SUVpvc levels. Unfortunately, the geno-
type sample size for HIF-1a: rs11549467 and EPAS1:
rs137853037 and rs137853036 SNPs was insufficient to
apply a statistical analysis (Table 3). No genotype of the
selected SNPs showed any significant association with
PET tracer uptake (Table 4).
We also classified the patients into subgroups
according to their SUV values (subgroup with high SUV
values versus low SUV values one, for both SUVmax
and SUVpvc). A Fisher’s exact analysis confirmed that
no significant association between PET tracer uptake
and specific SNP profiles exists.
Table 2 SUVmax and SUVpvc values
ID patient SUVmax SUVpvc
Pz1 3,93 3,62
Pz2 10,91 9,95
Pz3 5,68 5,83
Pz4 5,81 5,76
Pz5 8,62 7,19
Pz6 11,74 10,94
Pz7 4,08 4,35
Pz8 5,34 5,83
Pz9 9,25 8,66
Pz10 11,97 11,58
Pz11 12,85 10,29
Pz12 4,95 4,25
Pz13 10,59 9,89
Pz14 8,03 8,36
Pz15 14,61 19,15
Pz16 5,25 5,89
Pz17 4,12 4,01
Pz18 6,6 7,39
Pz19 2,79 3,22
Pz20 5,27 6,32
Pz21 9,23 7,81
Pz22 17,65 15,15
Pz23 2,82 3,13
Pz24 4,85 5,64
Pz25 1,95 2,64
Pz26 10,47 10,24
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rs710218 polymorphism is significantly associated with
SUVmax in combination with APEX1 rs1130409 SNP in
NSCLC disease [15]. To investigate its putative role in
FDG uptake in BC, we studied the association between
the GLUT1 rs710218 SNP and SUVmax and SUVpvc in
patients classified according the APEX1 rs1130409 geno-
type. The levels of SUVmax and SUVpvc were similar be-
cause p value was greater than 0.05 in all GLUT1
rs710218 genotype groups regardless the APEX1
rs1130409 genotype (Table 5).
MTHFR SNPs and FDG uptake association analysis
Considering that thromboembolism is a major complica-
tion in patients with BC, accompanied also by significant
morbidity and mortality [42], we decided to investigate the
role of thromboembolism-related SNPs in PET tracer
uptake. The rs1801133 and rs181131 SNPs of the 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene, en-
coding for a key enzyme in the folate metabolism pathway,have been associated with reduced enzyme activity and
hyperhomocysteinemia related with thromboembolic
events [43] and affect chemosensitivity of tumour cells. In
addition, Jakubowska A. and co-workers found that the
rs1801133 MTHFR SNP is associated with an increased
risk for breast and ovarian cancer [44,45]. MTHFR
rs1801133 allele frequencies and the percentages of the
three possible genotypes were calculated and deviations of
Hardy-Weinberg equilibrium were not observed [46]. No
genotype of rs1801133 showed any significant association
with PET tracer uptake, as revealed both by Mann-
Whittney and Fisher’s exact statistical analysis because
p value was greater than 0.05 (Table 4).Discussion
Today, a very limited number of reports describe possible
associations between FDG uptake and SNPs, rendering this
field poorly explored and clarified [13-18]. Our study inves-
tigated the possible simultaneous association between poly-
morphisms in GLUT1, HIF-1a, EPAS1, APEX1,VEGFA and
MTHFR genes and the FDG-PET uptake. To our know-
ledge, this is the first work that evaluates the collective im-
pact of the abovementioned SNPs on PET tracer uptake in
BC patients. FDG uptake, expressed in terms of SUVmax
or SUVpvc, is largely dependent on glucose metabolism.
High values are associated with reduced overall survival in
cancer patients [41].
GLUT1 is the primary transporter of glucose metabolism
and its over-expression has an important role in the sur-
vival and rapid growth of cancer cells. The rs841853 poly-
morphism of GLUT1 is located on the second intron of the
gene and as suggested by Kim SJ et al. [15], no change
would be expected in the GLUT1 protein sequence and ex-
pression. However, the GG genotype, which occurs in about
52% of the European population (data derived by dbSNP
Short Genetic Variations database) seems to be related to
FDG uptake in BC patients [14]. In our work, although we
did not observe deviation from the Hardy–Weinberg equi-
librium, we did not find the association between this SNP
and the FDG tumour uptake in BC.
The promoter region of the GLUT1 gene harbours an-
other SNP, rs710218 (named also SLC2A1 HpyCH4V),
positioned 400 bp upstream of a putative HIF-1a binding
site. Its close proximity to the hypoxia response ele-
ments (HRE) may modify the binding affinity of HIF-1
and thus alter the efficiency of the promoter and expres-
sion of GLUT1 [24]. In our study, the allele frequencies
of rs710218 SNP did not differ significantly from those
available in NCBI dbSNP database and no association
between this genetic alteration and SUVmax or SUVpvc
was found in BC patients, confirming similar data re-
cently obtained in NSCLC [15]. No significant associ-
ation with FDG uptake exists also when we examined
Table 3 SNPs analysis results
SNP n = 26 % Allele frequencies Hardy-Weinberg equilibrium
GLUT1 (rs841853)
GG 7 26,9 G = 0,442 p =0,13
TG 9 34,6 T = 0,558
TT 10 38,5
GLUT1 (rs710218)
AA 15 57,7 A = 0,788 p =0,17
AT 11 42,3 T = 0,212
TT 0 0
HIF1a (rs11549465)
CC 21 80,7 C = 0,904 p =0,59
CT 5 19,3 T = 0,096
TT 0 0
HIF1a (rs11549467)
GG 25 96,2 G = 0,981 p =0,92
GA 1 3,8 A = 0,019
AA 0 0
EPAS1 (rs137853037)
AA 26 100 A = 1 NA
AG 0 0 G = 0
GG 0 0
EPAS1 (rs137853036)
GG 26 100 G = 1 NA
GA 0 0 A = 0
AA 0 0
APEX1 (rs1130409)
TT 9 34,6 T = 0,596 p =0,84
TG 13 50 G = 0,404
GG 4 15,4
VEGFA (rs3025039)
CC 20 76,9 C = 0,846 p =0,04
CT 4 15,4 T = 0,154
TT 2 7,7
MTHFR (rs1801133)
CC 6 23,1 C = 0,442 p =0,47
CT 11 42,3 T = 0,558
TT 9 34,6
NA, not available.
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genotypes.
APEX1 promotes transcriptional activation of HIF-1
and its reduced levels are related to a decrease in
tumour volume and FDG uptake, suggesting that it af-
fects glucose metabolism and cellular proliferation [41].
Homozygosity (TT genotype) for the rs1130409 APEX1
SNP was significantly associated with a poor overallcancer survival [15]. Here, this genotype was not sig-
nificantly associated with SUV, compared with the
GG/TG genotypes, as previously shown by by Kim SJ
et al. [15].
HIF1a itself has an SNP (rs11549465) that we studied
for possible association with FDG uptake. However, we
observed no association in BC disease, in agreement
with data previously obtained in NSCLC [15].
Table 4 Association between genotype and SUVmax and SUVpvc values in BC patients
SNP SUVmax SUVmax SUVpvc SUVpvc
p -values* p -values*
SLC2A1 (rs841853)
GG GG 5,771 ± 2,475 0,1882 GG 5,619 ± 2,309 0,1067
TG GT + TT 8,366 ± 4,293 GT + TT 8,303 ± 4,135
TT
SLC2A1 (rs710218)
AA AA 7,497 ± 4,032 0,7988 AA 7,074 ± 3,200 0,6591
AT AT + TT 7,901 ± 4,175 AT + TT 8,271 ± 4,735
TT
HIF1a (rs11549465)
CC CC 7,387 ± 3,850 0,4861 CC 7,214 ± 3,237 0,6724
CT CT + TT 8,848 ± 4,948 CT + TT 9,118 ± 6,172
TT
APEX1 (rs1130409)
TT TT 6,607 ± 3,360 0,3388 TT 6,412 ± 3,051 0,3187
TG TG + GG 8,229 ± 4,310 TT + GG 8,119 ± 4,208
GG
VEGFA (rs3025039)
CC CC 8,107 ± 4,178 0,3875 CC 7,997 ± 4,038 0,3302
CT CT + TT 6,205 ± 3,307 CT + TT 6,193 ± 3,218
TT
MTHFR (rs1801133)
CC CC 8,415 ± 5,367 0,9292 CC 7,687 ± 4,390 0,9764
CT CT + TT 7,444 ± 3,661 CT + TT 7,549 ± 3,840
TT
* Mann Whitney-U Test.
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with BC risk and a C > T polymorphism at position 936
in the 3’ untranslated region of the VEGFA gene has
been associated with VEGF plasma levels. Specifically,
the T-variant is linked to lower VEGF level and associ-
ated with increased BC risk [13] and worse outcome
[17] compared to the wildtype allele. Wolf G. and co-
workers [13] suggested a potential role of this VEGFATable 5 Association between the rs710218 GLUT1 SNP and SU
APEX1 rs1130409 genotype
SNP Genotype GLUT1 rs710218 genotypes SUVm
APEX1 rs1130409 TT AA 6,735 ±
(n = 9) AT + TT 6,504 ±
TG AA 7,048 ±
(n = 13) AT + TT 8,525 ±
GG AA 11,040
(n = 4) AT + TT 10,145
*Mann Whitney-U Test.polymorphism on the variability of FDG uptake in
tumour tissue. However, our study and data reported by
Lorenzen S. et al. [17] do not confirm this association.
The MTHFR rs1801133 SNP is highly represented in
the Caucasian population [46] and it is related to in-
creased BC risk [36-38]. Nevertheless, its role in PET
has not been studied yet. Here, we evaluated its import-
ance in FDG uptake, for the first time, finding noVmax and SUVpvc values in BC patients according to
ax SUVmax p -values* SUVpvc SUVpvc p -values*
1,859 0,7302 6,408 ± 1,771 0,9048
4,467 6,416 ± 4,034
4,763 0,3301 6,931 ± 3,890 0,414
3,328 8,480 ± 2,413
± 2,560 >0,9999 9,050 ± 1,754 >0,9999
± 6,314 12,490 ± 9,419
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we still believe that additional studies are needed to
clarify its relevance.
Unfortunately, the genotype distributions for the
remaining HIF1a: rs11549467, EPAS1: rs137853037 and
rs137853036 SNPs did not allow us to evaluate their pos-
sible association with SUV.
The possible association between FDG uptake and
SNPs is described by a limited number of studies, due to
the need for multidisciplinary team and expertise. More-
over, this research field is characterized by controversial
reports.
Moreover a strong variability of FDG-PET uptake on
BC tissue has been reported [13], but the reason for this
variability is not fully understood and may involve various
cellular processes and risk factors such as genetic predis-
position. Overall, our analysis succeeded to reproduce
some previous findings, while we failed to confirm others,
which still need to be further investigated. These discrep-
ancies can be explained by the shortage of patients assayed
both in our work and previous studies [13-15].
In addition these works looked at different groups of
people from various European countries. Therefore it is
harder to compare findings and to draw conclusions: the
geographical and racial/ethnic distribution of an allele and
associated genotypes are considered extremely important
to fully understand the risk and the development of treat-
ments related to gene polymorphisms (sometimes the
allele frequency varies from region to region in the same
country) [47].
Concluding, none of the reported analyses included
functional evaluation of SNPs in FDG PET uptake. In our
work, the potentially useful polymorphisms were not
found associated with FDG uptake, using both SUVmax
and SUVpvc.
Taking into consideration the clinical impact of a signifi-
cant association between genetic alterations and PET-CT
could have in BC treatment and since current knowledge
is limited, additional and larger studies are required to
assess the importance of these genotypic variants in the
phenotypes or biological functions. Additionally, we can-
not exclude the possibility that unknown or known SNPs,
not investigated yet, in the same genes could have an im-
portant role.
Conclusions
This is the first report to our knowledge investigating the
association between a large panel of SNPs genotypes and
FDG uptake in BC patients. In this work we shown that
none of the nine potentially useful polymorphisms se-
lected and previously suggested by other authors were sta-
tistically correlated with FDG PET-CT tracer uptake
(using both SUVmax and SUVpvc). The possible func-
tional influence of specific SNPs on FDG uptake needsfurther studies in human cancer. Concluding, this work
represents a multidisciplinary and translational medicine
approach to study BC where the possible correlation be-
tween gene polymorphisms and tracer uptake may be con-
sidered to improve personalized cancer treatment and
care.
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